SIGA Technologies(SIGA)
$2.74-0.15 (-5.19%)
SIGA
SIGA Technologies stock drug pipeline
$2.74
At close:-0.15 (-5.19%)
Want to see SIGA full AI Analyst Report?
SIGA Technologies (SIGA) Drug Pipeline
495 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tpoxx | Smallpox | Phase III | Completed | Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days | Jun 23, 2021 | ― |
| Tecovirimat, Smallpox And Mpox Vaccine | Smallpox | Phase II | Active Not Recruiting | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS | Jun 23, 2021 | ― |
| Tecovirimat, Sevelamer Carbonate Oral Tablet, Sucroferric Oxyhydroxide Chewable Tablet, Calcium Acetate Oral Tablet, Lanthanum Carbonate Chewable Tablet | Smallpox | Phase IV | Completed | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders | May 11, 2020 | ― |
| Tpoxx | Smallpox | Phase IV | Completed | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG | May 06, 2020 | ― |
| Tecovirimat | Smallpox | Phase III | Completed | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat | Jun 01, 2015 | ― |
| Tecovirimat, St-246 400 Mg, St-246 600 Mg | Orthopoxviral Disease | Phase II | Completed | Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 | May 21, 2009 | ― |
| St-246 | Healthy | Phase I | Completed | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Feb 02, 2007 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Tpoxx | Phase III | Smallpox | Completed | Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days | Jun 23, 2021 | ― |
| Tecovirimat, Smallpox And Mpox Vaccine | Phase II | Smallpox | Active Not Recruiting | Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS | Jun 23, 2021 | ― |
| Tecovirimat, Sevelamer Carbonate Oral Tablet, Sucroferric Oxyhydroxide Chewable Tablet, Calcium Acetate Oral Tablet, Lanthanum Carbonate Chewable Tablet | Phase IV | Smallpox | Completed | Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders | May 11, 2020 | ― |
| Tpoxx | Phase IV | Smallpox | Completed | Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG | May 06, 2020 | ― |
| Tecovirimat | Phase III | Smallpox | Completed | A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat | Jun 01, 2015 | ― |
| Tecovirimat, St-246 400 Mg, St-246 600 Mg | Phase II | Orthopoxviral Disease | Completed | Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246 | May 21, 2009 | ― |
| St-246 | Phase I | Healthy | Completed | Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers | Feb 02, 2007 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Siga Technologies (SIGA) have in its pipeline
SIGA Technologies SIGA is currently developing the following drugs: Tpoxx, Tecovirimat, Smallpox And Mpox Vaccine, Tecovirimat, Sevelamer Carbonate Oral Tablet, Sucroferric Oxyhydroxide Chewable Tablet, Calcium Acetate Oral Tablet, Lanthanum Carbonate Chewable Tablet, Tecovirimat, Tecovirimat, St-246 400 Mg, St-246 600 Mg, St-246. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
